2-溴-6-(三氟甲氧基)苯并噻唑 | 628725-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-溴-6-(三氟甲氧基)苯并噻唑
• 英文名称: 2-bromo-6-trifluoromethoxybenzothiazole
• 英文别名: 2-bromo-6-(trifluoromethoxy)benzo[d]thiazole；2-bromo-6-(trifluoromethoxy)-1,3-benzothiazole
• CAS: 628725-99-5
• 化学式: C₈H₃BrF₃NOS
• 分子量: 298.083
• InChiKey: KDMNQLMJVHMDCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  289.4±50.0 °C(Predicted)
• 密度：
  1.830±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-溴-6-(三氟甲氧基)苯并噻唑 、 tert-butyl (2S)-2-{[(3aS,6S,6aR)-6-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl]carbonyl}pyrrolidine-1-carboxylate 在 potassium carbonate 、 copper(l) chloride 作用下， 以 对二甲苯 为溶剂， 以53%的产率得到tert-butyl (2S)-2-{[(3aS,6S,6aR)-6-methyl-5-oxo-4-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl]carbonyl}pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Pyrrolidine-5,5‘-trans-Lactams (5-Oxo-hexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma Stability

  摘要：

  A series of chiral, (S)-proline-alpha-methylpyrrolidine-5,5-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivatives of para-substituted phenyl ureas > para-substituted phenyl sulfonamides > para-substituted phenyl carboxamide for activity against HCMV deltaAla protease, producing para-substituted phenyl ureas with single figure nM potency (K-i) against the viral enzyme. The. SAR of the functionality on the lactam nitrogen has defined the steric and electronic requirements for high human plasma stability while retaining good activity against HCMV protease. The combination of high potency against HCMV deltaAla protease and high human plasma stability has produced compounds with significant in vitro antiviral activity against human cytomegalovirus with the 6-hydroxymethyl benzothiazole derivative 72 being equivalent in potency to ganciclovir. The parent benzothiazole 56 had good pharmacokinetics in dogs with 29% bioavailability and good brain and ocular penetration in guinea pigs.

  DOI：

  10.1021/jm030810w
• 作为产物：
  描述：

  利鲁唑 在 lithium bromide 作用下， 以 乙醇 、 氘代乙腈 为溶剂， 反应 16.0h， 生成 2-溴-6-(三氟甲氧基)苯并噻唑
  参考文献：
  名称：

  氨基杂环的脱氨基氯化

  摘要：

  对含杂原子芳族结构的选择性修饰需求量很大，因为它可以快速评估高级中间体中的分子复杂性。受自然界中脱氨酶选择性的启发，本文提出了一种简单的方法，可以将氨基杂环中的 NH 2基团视为掩蔽修饰句柄。借助简单的吡喃试剂和廉价的氯化物源，C( sp 2 )-NH 2可以转化为 C( sp 2)-Cl 键。该方法的特点是其广泛的官能团耐受性和底物范围，允许修饰超过 20 种不同类别的杂芳基基序（五元和六元杂环），具有许多敏感基序。NH 2以后期方式轻松转化为Cl，使从业者能够应用Sandmeyer-和Vilsmeier-型转化，而没有爆炸性和不安全的重氮盐、化学计量过渡金属或高氧化性和非选择性氯化剂的负担。

  DOI：

  10.1038/s41557-021-00812-0

文献信息

• TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：LI Wei

  公开号：US20100227859A1

  公开（公告）日：2010-09-09

  The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12, that may be involved in pathological disorders found in mammals, including a human.

  目前的教导与式I的化合物有关：及其药用盐和酯，其中R1、R2、R3、R4、X和Y如本文所定义。目前的教导还提供了制备式I化合物的方法以及抑制基质金属蛋白酶的方法，特别是可能参与哺乳动物中发现的病理性疾病，包括人类。
• [EN] DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY<br/>[FR] DÉRIVÉS D'HÉTÉROARYLSULFONAMIDES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPIE HUMAINE
  申请人：PF MEDICAMENT

  公开号：WO2012069503A1

  公开（公告）日：2012-05-31

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents −C(=O)-, or B represents CH when n=0 and D represents −CH2O− or when n=1 and D represents −O−, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺酰胺衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链C1-C4烷基，或直链或支链C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表−C(=O)-；当n=0时，B代表CH，D代表−CH2O−；当n=1时，B代表CH，D代表−O−，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链C1-C4烷基、直链或支链C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药用可接受盐。
• DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20130172326A1

  公开（公告）日：2013-07-04

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C 1 -C 4 alkyl, or linear or branched C 1 -C 4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents —C(═O)—, or B represents CH when n=0 and D represents —CH 2 O— or when n=1 and D represents —O—, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C 1 -C 4 alkyl, a linear or branched C 1 -C 4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺胺类衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链的C1-C4烷基，或直链或支链的C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表—C(═O)—，或当n=0时，B代表CH，D代表—CH2O—或当n=1时，D代表—O—，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链的C1-C4烷基、直链或支链的C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药学上可接受的盐。
• PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE
  申请人：Falb Eliezer

  公开号：US20130172364A1

  公开（公告）日：2013-07-04

  Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis.

  本发明涉及一种新型的丙炔基三氟甲氧基氨基苯并噻唑衍生物，其在治疗神经系统疾病中具有良好的疗效，包括帕金森病和多发性硬化症。
• US8759382B2
  申请人：——

  公开号：US8759382B2

  公开（公告）日：2014-06-24